KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Consolidated Net Income (2016 - 2025)

TherapeuticsMD's Consolidated Net Income history spans 16 years, with the latest figure at -$7000.0 for Q4 2025.

  • For Q4 2025, Consolidated Net Income fell 105.07% year-over-year to -$7000.0; the TTM value through Dec 2025 reached $84000.0, down 35.88%, while the annual FY2025 figure was $84000.0, 35.88% down from the prior year.
  • Consolidated Net Income reached -$7000.0 in Q4 2025 per TXMD's latest filing, down from $102000.0 in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of $127.2 million in Q2 2022 to a low of -$47.4 million in Q3 2021.
  • Average Consolidated Net Income over 5 years is $1.5 million, with a median of -$17000.0 recorded in 2025.
  • Peak YoY movement for Consolidated Net Income: skyrocketed 398.12% in 2022, then crashed 122.67% in 2025.
  • A 5-year view of Consolidated Net Income shows it stood at $50.2 million in 2021, then crashed by 41.68% to $29.2 million in 2022, then crashed by 97.75% to $658000.0 in 2023, then tumbled by 79.03% to $138000.0 in 2024, then crashed by 105.07% to -$7000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Consolidated Net Income are -$7000.0 (Q4 2025), $102000.0 (Q3 2025), and $6000.0 (Q2 2025).